Skip to main content
SpringerLink
Log in

Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline?

A 1-year follow-up study of women

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

A prospective study was carried out to assess the early and later alterations in left and right ventricular diastolic and systolic function after the termination of anthracycline therapy. In 33 women without cardiac disease who were treated by anthracycline therapy, cardiac function was evaluated by radionuclide angiography before the treatment (T0) and 1 month (T1) and 12 months (T12) after the end of the treatment. Cardiac function was assessed by radionuclide measurement throughout treatment. Analysis of ejection fraction (EF), peak ejection rate (PER), time to PER (TPER), peak filling rate (PFR) and time to PFR (TPFR) was performed before and after treatment. To normalise radionuclide measurements of the ventricular diastolic function, the ratio of the PFR and the EF and the ratio of the PFR and the PER were calculated. No patient developed symptomatic congestive cardiac failure. One-way analysis of variance showed a significant decrease in the three parameters (EF, PER, PFR) over time only for the left ventricle (LV); no significant alterations appeared for the right ventricle (RV). The EF of the LV decreased from 59%±5% at To to 57%±6% at T1 and 56%±5% at T12. The PER of the LV fell from 3.03±0.40 end-diastolic volume per second (EDV/s) at T0 to 2.79±0.47 at T1 and 2.78±0.43 at T12. The PFR of the LV dropped from 2.99±0.43 EDV/s at T0 to 2.62±0.44 at T1 and 2.56±0.42 at T12. For the normalised ratios, no differences were observed. Significant differences were found for EF, PER and PFR between T0 and T1, and between T0 and T12, but no difference was found between T1 and T12. This report shows simultaneous impairment of the systolic and diastolic LV radionuclide parameters at 1 and 12 months after anthracycline therapy without alteration in the RV function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cincangiography.N Engl J Med 1979; 300: 278–283.

    Google Scholar 

  2. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy.Am J Med 1987; 82: 1109–1118.

    Google Scholar 

  3. Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart.Br Heart J 1993; 70: 499–502.

    Google Scholar 

  4. Morgan GW, Mc Ilveen BM, Freedman A, Murray IPC. Radionuclide ejection fraction in doxorubicin cardiotoxicity.Cancer Treat Rep 1981; 65: 629–638.

    Google Scholar 

  5. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO. Doxorubicin cardiotoxicity: assessment of late ventricular dysfunction by radionuclide cineangiography.Ann Intern Med 1981; 94: 430–435.

    Google Scholar 

  6. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.Am Heart J 1983; 388: 278.

    Google Scholar 

  7. Druck MN, Gulenchyn KY, Ens WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity.Cancer 1984; 53: 1667–1674.

    Google Scholar 

  8. Parmentier S, Melin JA, Piret L, Beckers C. Assessment of left ventricular diastolic function in patients receiving anthracycline therapy.Eur J Nucl Med 1988; 13: 563–567.

    Google Scholar 

  9. Lee BH, Goodenday LS, Muswick GJ, et al. Alterations in left ventricular diastolic function with doxorubicin therapy.J Am Coll Cardiol 1987; 9: 184–188.

    Google Scholar 

  10. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics.Am Heart J 1989; 118: 92–98.

    Google Scholar 

  11. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls.Med Pediatr Oncol 1993; 21: 477–479.

    Google Scholar 

  12. Hrushesky JM, Darrel DA, Tewksbury DA. Doxorubicin clearance in the obese.J Clin Oncol 1988; 6: 1321–1327.

    Google Scholar 

  13. Dantchev D, Balercia G, Bourut C, et al. Comparative microscopic study of cardiotoxicity and skin toxicity of anthracyclin analogs.Biomed Pharmacother 1984; 38: 322–328.

    Google Scholar 

  14. Marie PY, Marçon F, Brunotte F, Briançon S, Danchin N, Worms AM, Robert J, Pernot C. Right ventricular overload and induced sustained ventricular tachycardia in operatively “repaired” tretralogy of Fallot.Am J Cardiol 1992; 69: 785–789.

    Google Scholar 

  15. Lee KJ, Southee AE, Bautovich GJ, et al. Normalised radionuclide measures of left ventricular diastolic function.Eur J Nucl Med 1989; 15: 123–127.

    Google Scholar 

  16. Janicki IS, Weber KT. Factors influencing the diastolic pressure volume relation of cardiac ventricles.Fed Proc 1980; 39: 133–140.

    Google Scholar 

  17. Bristow MR, Lopez MB, Mason JW, et al. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin.Cancer 1982; 50: 32–41.

    Google Scholar 

  18. Palmieri ST, Bonow RO, Myers CE, et al. A prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.Am J Cardiol 1986; 58: 607–613.

    Google Scholar 

  19. Lorell BH, Barry W. Effects of verapamil on contraction and relaxation of cultured chick embryo ventricular cells during calcium overload.J Am Coll Cardiol 1984; 3: 341–348.

    Google Scholar 

  20. Cottin Y, Touzery C, Coudert B, et al. Impairment of diastolic function during short-term anthracycline chemotherapy.Br Heart J 1995; 73: 61–64.

    Google Scholar 

  21. Pelikan PC, Weisfeldt ML, Jacobus WE, et al. Acute doxorubicin cardiotoxicity: functional, metabolic and morphologic alterations in the isolated perfused rat heart.J Cardiovasc Pharmacol 1986; 8: 1058–1066.

    Google Scholar 

  22. Lazzarino G, Violla AR, Mulieri L, et al. Prevention by fructose-1,6-diphosphate of cardiac oxidative damage induced in mice by subchronic doxorubicin treatment.Cancer Res 1987; 47: 6511–6516.

    Google Scholar 

  23. Myers CE, Liss RH, Ifrim I, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.Science 1987; 197: 165–167.

    Google Scholar 

  24. Porta EA, Joun NS, Matsumura L, et al. Acute adriamycin cardiotoxicity in rats.Commun Chem Pathol Pharmacol 1983; 41: 125–137.

    Google Scholar 

  25. Bachur NR, Goron SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals.Cancer Res 1978; 38: 1745–1750.

    Google Scholar 

  26. Kusuoka H, Futaki S, Koretsune Y, et al. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure.J Cardiovasc Pharmacol 1991; 18: 437–444.

    Google Scholar 

  27. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review.J Mol Cell Cardiol 1987; 19: 101–111.

    Google Scholar 

  28. Thompson RC, Canby RC, Lojeski EW et al. Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties.Am Heart J 1987; 113: 1444–1449.

    Google Scholar 

  29. Cottin Y, Ribuot C, Maupoil V, et al. Early detection of adriamycin cardiotoxicity evaluated by proton nuclear magnetic resonance relaxation.Can J Physiol Pharmacol 1994; 72: 140–145.

    Google Scholar 

  30. Cross CE, Rieben PA, Salisbury PF. Influence of coronary perfusion and myocardial edema on pressure-volume diagram of LV.Am J Physiol 1961; 201: 102–108.

    Google Scholar 

  31. Steinhertz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy.JAMA 1991; 266: 1672–1677.

    Google Scholar 

  32. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.Br Heart J 1986; 55: 274–282.

    Google Scholar 

  33. Bu'Lock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.Br Heart J 1993; 70: 185–188.

    Google Scholar 

  34. Siveski-Iliskovic N, Hill M, Chow DA, et al. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect.Circulation 1995; 91: 10–15.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Médecine Nucléaire, Centre Georges François Leclerc, Rue du Professeur Marion, F-21034, Dijon Cedex, France

    Yves Cottin, Claude Touzery, Sylvie Richebourg, Martine Cohen, Michel Toubeau & François Brunotte

  2. Service d'Oncologie Médicale, Centre Georges François Leclerc, Dijon, France

    Bruno Coudert

  3. Centre de Cardiologie, Hôpital du Bocage, Dijon, France

    Pierre Louis & Jean Eric Wolf

Authors
  1. Yves Cottin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claude Touzery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Coudert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvie Richebourg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martine Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michel Toubeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pierre Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean Eric Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. François Brunotte
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cottin, Y., Touzery, C., Coudert, B. et al. Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline?. Eur J Nucl Med 23, 511–516 (1996). https://doi.org/10.1007/BF00833384

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00833384

Key words

Search

Navigation